

Gavi 6.0 New Country Application Narrative

This narrative template is required for the country application submission for countries requesting new funding in the Gavi 6.0 period. The narrative should be submitted along with the budget, vaccine details, and the Grant Accountability Framework (GAF). The narrative is used to articulate how the country's Cash Budget for the Gavi 6.0 strategy period (2026–2030) will strengthen routine immunisation, improve equity and sustainability of programmes, and support new vaccine introductions and preventive campaigns. For further guidance to complete this narrative, please refer to the [Gavi 6.0 Funding Guidelines](#).

Both this narrative and the budget must adhere to Gavi's three **mandatory guardrails**: (1) a minimum of 10% of the cash grant must be allocated to civil society organisations (CSOs); (2) a minimum investment in cold chain equipment procurement and maintenance, as defined in the Gavi 6.0 Funding Guidelines, must be ensured; and (3) funds must be allocated for measles and measles-rubella follow-up campaigns within range communicated.

This narrative consists of **four mandatory sections** for countries to complete.

1. [Country Context](#)
2. [Goals, Design, and Strategic Alignment](#)
3. [Implementation Support and Management](#)
4. [Risks and Mitigation](#)

It also contains six annexes. Countries **only need to complete the annexes that apply**. Each section will indicate which annex to complete based on the selections made.

- [Annex A: Vaccine and Campaign Support Supplement – within 3 years of application submission](#)
- [Annex B: Vaccine and Campaign Support Supplement – 3 years after application submission](#)
- [Annex C: Cold Chain Equipment \(CCE\)](#)
- [Annex D: Diagnostics Support](#)
- [Annex E: Vaccine Optimisation Support \(within 3 years of application submission\)](#)
- [Annex F: Vaccine budget simulation tool supplemental narrative](#)

1. Country Context

This section comprises three parts: Country Context, Immunisation Programme Context, and Immunisation Programme Challenges. Together, they set the context for the country's request.

1.1 Country Context

Please use content from the most recent National Immunisation Strategy (NIS) or health sector strategy document to describe the country context including:

- Key country characteristics, including demographics, birth cohort, and zero-dose children
- Economic, political, and societal factors influencing primary healthcare and the immunisation programme
- Fragility and/or humanitarian settings
- Key challenges and gaps affecting primary healthcare and immunisation programme delivery and performance

Country response...

1.2 Immunisation Programme Context

Since the latest NIS, health sector plan, or equivalent, have there been any significant changes in the country context that affect the national immunisation programme? This could include changes in immunisation coverage; epidemiological, economic, political, societal, or environmental changes, new vaccine introductions.

- ☐ **Yes** Please describe below
- ☐ **No**

Country response...

1.3 Immunisation Programme Challenges

Since the latest NIS, health sector plan, or equivalent, have any significant new health system-related barriers or gaps emerged affecting immunisation programme delivery, equity, and/or sustainability?

Focus on the most critical health system constraints. This could include service delivery, workforce, supply chain, data systems, financing, demand, governance, gender-related barriers.

- ☐ **Yes** — Please describe below
- ☐ **No**

Country response...

2. Goals, Design, and Strategic Alignment

This section comprises seven parts: Prioritisation of Gavi Support, Goals and Objectives, Investment Areas and Activities, Zero Dose and Gender Barriers, Complementarity and Integration, and Multilateral Development Bank (MDB) Alignment. Together, they clarify the request for Gavi support and its intended use.

2.1 Prioritisation of Gavi support

Gavi encourages countries to undertake a portfolio prioritisation process to inform the development of Gavi application in line with national priorities. Please refer to the prioritisation guidance in [Annex 1 of the Gavi 6.0 Funding Guidelines](#).

Has the prioritisation exercise been conducted in your country?

- ☐ **Yes** — Please provide a summary of the prioritisation process below. Include how it was conducted, what stakeholders were involved, the criteria, rationale and evidence used, and any changes made based on lessons learned from past implementation. Briefly explain the key strategic trade-offs considered during the prioritisation process, including how constraints informed choices about where Gavi support would be concentrated versus reduced.
- ☐ **No**

Country response...

2.2 Goals and Objectives

What objectives are prioritised for Gavi support, including cash and vaccine budgets, and how do they contribute to the goals of the health sector and immunisation programme?

Country response...

2.3 Investment Areas and Activities

Select the areas for Gavi support below and **describe** the planned activities, particularly those taking place in the **first two years** of the grant and how they will address the gaps and challenges identified. Complete the corresponding annexes as indicated.

For each investment area selected, please describe:

- The **geographic focus** of the proposed Gavi investments including a description of any focused efforts at sub-national level or in high zero-dose burden communities.
- How these regions or communities were identified and selected.
- As relevant, describe any **flagship interventions** planned as described in the [Gavi 6.0 Funding Guidelines](#).

Reference documents for additional guidance:

- *For the scope and requirements for new **vaccine introductions, diagnostics, and vaccination campaigns** anticipated during the implementation period, refer to [Annex 3 of the Gavi 6.0 Funding Guidelines](#).*
- *For **cold chain support**, refer to the [CCE Programme and Technology Guide](#) for the CCE programme changes, eligible product and services, and deployment modalities, including the eligibility and criteria for the country-led deployment approach.*
- *For **Health System Investment Areas**, refer to [Annex 4 of the Guidelines](#).*

Select areas for Gavi support:

- ☐ New vaccine and/or diagnostics introduction(s) – **Complete Annex [A](#), [B](#), or [D](#)** as applicable
- ☐ Measles / Measles-Rubella follow up vaccination campaign – **Complete Annex [A](#) or [B](#)** as applicable
- ☐ Other vaccination campaign(s) – **Complete Annex [A](#) or [B](#)** as applicable
- ☐ Cold chain equipment procurement - **Complete [Annex C](#)**
- ☐ Product switch requests – **Complete Annex [E](#)**
- ☐ Health Systems and Immunisation Strengthening (HSIS) Investment Areas:
 - Service delivery
 - Demand generation and community engagement
 - Human resources for health
 - Governance and management
 - Supply chain
 - Data, Monitoring, and Learning
 - Vaccine-preventable disease surveillance, laboratory capacities, and diagnostics
 - Health financing
 - Other (*please specify*)

Country response...

2.4 Zero Dose and Gender Barriers

How will the proposed activities address barriers to improve equity and sustainably identify and reach zero-dose children and missed communities?

Please describe:

- How the proposed activities will address gender-related barriers to immunisation access, uptake and service retention.
- Where relevant, how displaced populations, including refugees, are considered within your immunisation programme.

Country response...

2.5 Complementarity and Integration

How will Gavi support align with broader health sector and other immunisation financing, priorities, and programmes?

Please describe:

- Complementarity to domestic funding and other development partner assistance (e.g., the Global Fund).
- Integration with or complementary to relevant programmes such as primary health care (PHC), malaria programmes, the Global Polio Eradication Initiative (GPEI), water, sanitation and hygiene (WASH), Neglected Tropical Diseases (NTDs), nutrition, or health campaigns.

Country response...

2.6 Multilateral Development Bank (MDB) Alignment

Is the country currently considering, preparing, or implementing any health, nutrition, maternal and child health, education, or WASH project in collaboration with a Multilateral Development Bank (MDB) — such as the World Bank, Asian Development Bank, or Asian Infrastructure Investment Bank — that could present opportunities for alignment or pooling of financing with Gavi support?

- ☐ **Yes** — Please describe the project(s), including the timeline for project development, stage of preparation, and potential areas of alignment. Where relevant, also specify key co-financiers or partners, the financing instrument (e.g., IDA grant/credit/loan), and whether results and MEL frameworks are aligned or coordinated with Gavi support.
- ☐ **No**

Country response...

3. Implementation Support and Management

This section comprises four parts: Technical Assistance, Civil Society Organisation (CSO) Engagement, Sustainability, and Performance Management. Together, they outline how the grant will be implemented and sustained.

3.1 Technical Assistance

Please describe the technical assistance needs for successful implementation of the prioritised investments.

Country response...

3.2 Civil Society Organisations (CSO) Engagement

How will CSOs support immunisation delivery in missed and under-served communities in the country context?

Please describe:

- The main activities CSOs will carry out.
- The geographical areas where they will work.
- The amount allocated to CSOs.
- The proposed funding mechanism for channelling funds to them.

Note that specific CSOs cannot be named at the application stage, as they will be identified through a competitive selection process following approval of the application. As a reminder, a minimum of 10% of the cash grant must be allocated to CSOs, as per the mandatory guardrails outlined in the Gavi 6.0 Funding Guidelines.

Country response...

3.3 Coordination and Performance Management

Please describe the governance and coordination mechanisms to oversee grant implementation at national and sub-national levels, including monitoring, evaluation, and regular performance reviews for scaling of best practices and correcting under-performance.

This space should also be used to further explain the targets set in the Grant Accountability Framework (GAF), as further described in the [Gavi 6.0 Funding Guidelines](#), how these will be monitored and plans for supplemental evidence generation activities (e.g. surveys, research, evaluations).

Country response...

3.4 Sustainability

Please describe how activities will be sustained after this Gavi grant ends. Specify which activities are expected to transition to domestic or other financing within or after the grant period.

Country response...

4. Risks and Mitigation

This section comprises one part: Risk Management. It outlines the risks to grant implementation and how they will be managed.

4.1 Risk Management

Please identify risks that could affect grant implementation and the achievement of results. Describe how these risks will be mitigated. Risks may be technical, operational, financial, political, capacity-related, external, or other.

Please complete the table below for each identified risk.

Risk	Mitigation Measure
<i>Describe the risk and how it could affect immunisation programme delivery and outcomes.</i>	<i>Describe the actions to manage this risk.</i>

Annex A: Vaccine and Campaign Support Supplement – within 3 years of application submission

If vaccine and campaign support has been selected in [Section 2](#), please complete this annex.

This annex comprises 12 parts. Please use it to provide information for any request for new vaccine and/or campaign support, for activities to be implemented **within 3 years** of the grant start date. For example, if the grant starts in January 2027, this covers vaccine and campaign support through 2029. This includes new routine introductions, malaria scale-ups, and catch-up or preventive campaigns.

It is **not necessary to duplicate information** already provided elsewhere in the application. If the information is already covered elsewhere, or in a separate introduction plan or plan of action please provide a **clear reference**, including document, section, and page number. Use this annex only for information **not already covered**.

A.1 Summary of new vaccine support

Please list the vaccine programme(s) for which you are applying, including the month and year targeted for the launch.

Country response...

A.2 Epidemiological and programmatic justification for new support request

Please provide the epidemiological and programmatic justification for prioritising the planned new vaccine introduction and the timing, in line with national immunisation priorities and Gavi 6.0 programme eligibility and strategic objectives.

Where applicable, please include a justification for national vs subnational targeting, and explain which complementary delivery strategies (e.g. periodic intensification of routine immunisation (PIRI)) may be used in the areas not targeted by the campaign.

Country response...

A.3 Country governance process (decision-making, endorsement, and coordination)

Describe the process that led to the approval of these vaccine investments.

Please include:

- The recommendation from the NITAG (or equivalent body).
- The Ministry of Health's approval, and any Vaccine Prioritisation exercises or analyses.
- Where available, include the relevant meeting minutes or documentation supporting these decisions.
- For campaigns, describe plans to establish or strengthen a committee/commission, where one already exists, to monitor readiness and campaign performance and support collaboration with the Ministry of Education.

Country response...

A.4 Target population and dosing

Describe, separately for each vaccine, the target population, dose schedule, and rationale for each applicable vaccine, and indicate any excluded populations (e.g., pregnant women).

Country response...

A.5 Service delivery and integration

What is the proposed service delivery strategy, including coordination or integration across antigens and tailored approaches for special, vulnerable, or hard-to-reach populations?

Please describe:

- Integration opportunities within or beyond EPI, including campaigns planned within 12 months and functions to be integrated.
- What relevant stakeholders and programmes such as polio, neglected tropical diseases, school health, maternal and child health, primary health care will support planning, coordination, and decision-making.
Integration may include shared microplanning, training, supervision, logistics, and monitoring and evaluation; it does not require co-administration or co-delivery.
- How routine immunisation screening and/or vaccination will be implemented during introductions or campaigns.
- How campaign and routine immunisation doses will be recorded, reported, and monitored.

Country response...

A.6 Demand Generation & community engagement

Describe demand generation and community engagement approaches to support uptake of the selected vaccine(s), including social mobilisation methods, communication, and advocacy. Please link this to approaches that have worked or not worked in recent introductions or campaigns.

Country response...

A.7 Human Resources for Health

What are the human resource requirements to support delivery of the selected vaccine(s)?

Describe:

- Any additional workforce needs, training, supervision, and task-shifting approaches.
- Operation of vaccination posts for campaigns (number of teams, vaccinator workload per day) based on WHO guidance, for each campaign strategy (e.g. fixed post, mobile).

Country response...

A.8 Supply Chain

Please describe supply and cold chain readiness for each applicable vaccine, including whether there is sufficient cold chain space, and if Controlled Temperature Chain (CTC) methods are to be deployed.

Country response...

A.9 Data and digitally enabled information and payment systems

A.9.1 Data and health information systems readiness

Please describe the readiness of data and health information systems for each applicable vaccine introduction, scale-up, or campaign.

For campaigns, outline arrangements for pre-, intra-, and post-campaign data collection, data flow, and how data will be used to monitor performance and guide timely action.

Country response...

A.9.2 Artificial intelligence and digital innovation

If artificial intelligence (AI) or digital innovations are leveraged, describe how these will be used and outline measures to ensure their responsible, ethical, and secure use.

Country response...

A.9.3 Digital payment readiness

Please describe the current state of end-to-end digital payment readiness for this campaign, covering the full payment lifecycle from health worker enumeration, enrolment, registration, and account onboarding through to payment delivery, reconciliation, reporting, and issue resolution.

Country response...

A.9.4 Enablers, constraints, and risks

Please identify the key enablers, constraints, risks, and remaining actions and support required to achieve implementation readiness.

Country response...

A.10 Vaccine Preventable Disease (VPD) surveillance

How is the VPD surveillance system is linked to vaccination?

Describe:

- How cases are detected and reported.
- How surveillance data are used to guide immunisation strategies, monitor programme performance, and inform response activities.

Country response...

A.11 Adverse Event Following Immunisation (AEFI)

Please describe the processes in place for the identification, management, reporting and communication of adverse events following immunisation (AEFI).

Please include:

- How AEFI will be detected and assessed.
- How cases will be managed and referred where needed, the reporting pathways and timelines.
- How communication with caregivers, communities, health workers and other relevant stakeholders will be handled.

Country response...

A.12 Campaign Monitoring

For campaigns, what are the plans for monitoring the performance of the campaign – both intra-campaign and post-campaign?

- **Intra-campaign:** Monitoring should be context-adapted and ensure that real-time corrective action to implementation can be driven by real-time data (this should include plans and triggers for mop-up vaccination).
- **Post-campaign:** Post Campaign Coverage Surveys (PCCS) remain the gold standard. However, countries can now instead choose context-relevant approaches (e.g. RCM, LQAS, or PCCS). Clarify which approach will be used and how the data will be used for strengthening routine immunisation and campaign outcomes.

Country response...

Annex B: Vaccine and Campaign Support Supplement – 3 years after application submission

If vaccine and campaign support was selected in [Section 2](#), please complete this annex as relevant.

This annex comprises four parts. Please use it to provide information for new vaccine introductions (NVI) and campaigns happening **after three years** from the date of application. For example, a country application submitted in 2026 would cover NVIs and campaigns planned for 2030.

B.1 Summary of new vaccine support

Please list the vaccine programme(s) for which you are applying support for including the month/year targeted for the launch. If a specific vaccine product or presentation is planned, please describe.

Country response...

B.2 Epidemiological and programmatic justification for new support request

Please briefly describe the programmatic and epidemiological justification for the request. Please describe how the vaccine was prioritised.

Country response...

B.3 Country governance process (decision-making, endorsement, and coordination)

Is there already regulatory approval for the vaccine product from the National Regulatory Authority and if not, what is the timing for obtaining the approval?

Country response...

B.4 Target population and programme design.

Please briefly summarise the proposed programme design, target population, geographic targeting, delivery schedule, and introduction approach. If there is a campaign, please summarise plans for integration (from planning to implementation).

Country response...

Annex C: Cold Chain Equipment (CCE)

If the cold chain procurement investment was selected in [Section 2](#), please complete this annex. This annex comprises four parts. Please use it to provide information on CCE systems, investments, deployment and maintenance plan.

C.1 Cold Chain System Overview

Please provide an overview of the cold chain system and infrastructure status, including key gaps and total CCE needs for the grant period. This should include the existing inventory update system, including the year of the last update.

Country response...

C.2 Cold Chain Investment

How will Gavi support help address the CCE gaps and complement existing CCE capacities?

Please include:

- How Gavi support for CCE was prioritised (e.g. replacement, expansion or extension).
- The total CCE budget (Gavi, country, procurement fees) and describe the funding source, status for the joint investment and any funding gaps that will not be addressed.
- A justification where CCE needs are lower than the CCE minimum floor communicated.

Country response...

C.3 Equipment Deployment Plan

Please select which deployment modality has been chosen and explain the rationale and the associated risks and mitigation strategies.

- ☐ **Supplier-led**
- ☐ **Country-led** — Please upload the country led deployment toolkit

Country response...

C.4 Cold Chain Equipment Performance Monitoring and Maintenance

How will the cold chain equipment be monitored and maintained to ensure reliable operation over time?

Please describe:

- The preventive and curative maintenance system in place.
- Key barriers and proposed interventions to strengthen the system, including who will carry out the maintenance and repairs.
- How data will inform decisions, and how maintenance, including spare parts, will be funded.

Country response...

Annex D: Diagnostics Support

If new diagnostics support was selected in [Section 2](#), please complete this annex.

This annex comprises 13 parts. For any new diagnostics support request, please refer to Gavi's 6.0 Funding Guidelines: [Part A, 4](#) and [Part E, Annex 3](#) for relevant guidance.

Please respond to the questions below for the disease(s) for which you are applying for diagnostics support. In addition to the information provided in this form, please **attach any existing documents** that would provide further information relevant to this application. In some instances, Gavi requires the use and inclusion of specific tools or templates. These instances are mentioned and reflected in Annex 4 of the Application Checklist.

Please select the disease(s) for which you are applying for new diagnostics support:

- ☐ Cholera
- ☐ Yellow Fever
- ☐ Measles

D.1 Rationale for the request

Briefly describe how expanded diagnostic capacity fits into your country's plan for controlling and/or eliminating the disease for which you are requesting support.

Country response...

D.2 Epidemiology

Please complete the following table for each diagnostic requested to detail the disease situation over the past five years (or three for Yellow Fever), including information on suspected and confirmed cases, with reference to relevant test type.

Disease:					
Year	Number of suspected cases	Number of cases tested by RDT	Number of RDT positive cases	Number of cases tested by culture/ PCR	Number of culture/ PCR positive cases
2025					
2024					
2023					
2022					
2021					

Please add more tables for all relevant disease

D.3 Surveillance and Laboratory Testing

Describe current surveillance performance and laboratory-based surveillance testing capacity gaps.

Please include:

- Information on relevant electronically linked data reporting systems.
- Information on laboratory referral system (including variability, if any, by disease).
- Information on specimen transport.
- How surveillance results inform (vaccination and other) decision making.
- How improved surveillance testing capacity will result in accelerated case identification, outbreak confirmation, and vaccine implementation.

Country response...

D.4 Target Population

Please describe how testing will cover suspected cases detected through national surveillance, with emphasis on high- and moderate-risk areas identified by WHO.

Equity should be considered by ensuring national coverage across high-risk zones and referral systems from peripheral sites to reference labs.

Country response...

D.5 Volume Request

Please detail the total requested volumes, broken down by year and by technology type (for Yellow Fever).

- If applying for Cholera diagnostic support, a supporting Cholera Diagnostics Quantification excel file is available on request from Gavi.
- If applying for measles diagnostic support, please refer to the WHO's Global Measles and Rubella Laboratory Network (GMRLN) guidelines.

Country response...

D.6 Supply Delivery – Port of Entry and Contact

To facilitate timely delivery of supplies, the country will be responsible for providing the green light to UNICEF to enable the scheduling of shipments with UNICEF Supply Division.

Provide the **name**, **address** and, if available, **geocoordinates** of the first international airport of entry on CIP, Named Airport that UNICEF Supply Division will ship all diagnostics tests to. Please share relevant details, if variability by disease.

Country response...

Please identify at least one point of contact at the desired delivery location and provide their **name**, **phone number** and **e-mail address** below. If the application is approved, UNICEF will reach out to that person to discuss delivery of supplies.

Country response...

D.7 Customs

The country is responsible for paying or securing waiver of customs clearance, insurance, handling, and storage upon arrival of diagnostic equipment.

What is the country's plan for securing the necessary customs clearance and any other import authorizations, e.g., tax waivers? Please share relevant supporting documentation and include relevant details, if variability by disease.

Country response...

D.8 In-Country Distribution

The country is responsible for storage of diagnostic tests in suitable (e.g., appropriate temperature) locations and distributing them from the previously identified port of entry to lower levels and health facilities.

Please provide brief details on the medical supply chain system in-country and provide examples of the ability to distribute diagnostic tests from central to lower levels.

Country response...

D.9 National Regulatory Agency

Please provide information on the National Regulatory Agency in the country, including presence of a regulator of medical devices and in-vitro diagnostics (IVDs). Please identify at least one point of contact with phone number and e-mail address at the National Regulatory Agency. UNICEF will need to communicate authorization requirements to manufacturers.

Country response...

D.10 Data management and Programmatic Reporting

Please describe the process by which data will be systematically reported to WHO following the relevant disease-specific guidelines and templates (i.e. Cholera – GTFCC, Yellow Fever – WHO GYFLaN, Measles – WHO GMRLN). This includes reporting of; Number of suspected cases, Number of cases tested (total and by test method), Number of positive cases, and Number of deaths.

Note: Countries may also be asked to provide information on diagnostic testing through surveys. Gavi expects that (i) future renewal requests for diagnostic equipment, and (ii) future applications for preventative campaigns support should reflect improved diagnostic capabilities and reporting. Gavi requires that country applications for Gavi funding support

for reactive and preventive campaigns use data from routine testing to substantiate plans on where such campaigns should be conducted.

Country response...

D.11 Diagnostic Procurement Funding

While no cost-sharing requirement is requested in the current window of support (i.e. until end of 2030), a cost-sharing requirement will eventually be introduced for diagnostics support. More information will be provided by your Gavi Senior Country Manager (SCM) as it becomes available. To ensure long-term financial sustainability, countries will be expected to eventually contribute some of their resources and gradually assume full responsibility for funding cholera diagnostics.

Please provide information about the domestic budget for diagnostic testing supplies and equipment procurement for this fiscal year and, if available in future years.

Country response...

D.12 Surveillance Systems Funding

Operational funding for introduction or expansion of diagnostic funding is not available through this mechanism. Revision of surveillance guidelines, training, development of reporting tools, and distribution of diagnostic tests should be funded through other means.

Please include:

- Information about any existing or planned funding and activities for surveillance training and other surveillance strengthening activities.
- Details about the source of funding, e.g., domestic funding, Gavi's Health Systems Strengthening (HSS) funding, or support from other partners.

Country response...

D.13 Integration

Please describe how the requested diagnostic support will be integrated with national immunisation programmes, Integrated Disease Surveillance and Response (IDSR), coordinated technical assistance to support training, and performance monitoring through quality assurance and control, proficiency panel and laboratory assessments.

Country response...

Annex E: Vaccine Optimisation Support – within 3 years of application submission

If vaccine optimisation support has been selected in [section 2](#), please complete this annex.

This annex comprises four parts. Please use this section to provide the necessary information to request to switch to a different vaccine product, presentation, schedule or use across the vaccine portfolio. For definitions and requirements, please consult the [Gavi 6.0 Funding guidelines](#).

To complete the table below, use the **exact vaccine product and presentations** description as provided in [Gavi's Detailed Product Profiles list](#) when completing the information below for each of your switch requests.

If there is a planned switch to a presentation/product that is currently not in the Gavi menu (e.g. HPV9), please include it as indicative in the table below, noting a contingency action in case it is not available by the planned switch date.

Switch from:	Switch to:	Planned switch date (DD/MM/YYYY)	Contingency action if not yet on Gavi Menu at switch date

Add rows as needed

E.1 Country context

E.1.1 Reason for switch request

Select the reason for the switch request below. For example, for Gavi Alliance requests, this could be example due to policy changes or supply disruptions.

- Gavi Alliance request ☐ **Yes** ☐ **No**
- Country's elective choice ☐ **Yes** ☐ **No**

If **country's elective choice** is selected, please describe the rationale. Please indicate the drivers for this switch, such as cost considerations (e.g. wastage, price), vaccine's clinical profile, logistic considerations, programmatic suitability, epidemiological/strategic considerations or other.

Country response...

E.1.2 Programmatic eligibility criteria for this switch

Please elaborate on how the country fulfils the programmatic requirements (if applicable).

Note that for a PCV 1+1 schedule switch, countries must demonstrate strong population immunity (e.g., ≥80% average PCV3 coverage over the past 5 years or evidence of low vaccine-type disease/carriage) and a robust second year-of-life vaccination platform (≥80% average MCV1 or equivalent coverage over the past 5 years). Additional desirable criteria include a cost–benefit assessment and adequate disease surveillance capacity.

Country response...

E.1.3 Routine Vaccination

Has routine vaccination already started? ☐ Yes ☐ No

Note that some countries approved with one product have had to switch before launch due to unavailability.

E.1.4 Stock Levels

Has the country experienced stock-out of this antigen over the past 12 months?

☐ Yes ☐ No

Please provide the current stock level of the current presentation(s) in the table below. If applicable, indicate whether routine or campaign doses.

Antigen:		
	Routine (number of doses/ months of stock)	Campaign (number of doses)
Central level		
Second level		
Third level		

Please add more tables for relevant antigens

E.1.5. Off label use

Does the implementation include off-label use? ☐ Yes ☐ No

If **yes**, has a national policy change been agreed to? ☐ Yes ☐ No

E.1.6 Licensing

Is the new presentation licensed in the country? ☐ Yes ☐ No

If **no**, please provide the time to obtain a license or approval and specify whether national regulations allow for waiver or expedited registration procedure of a WHO Prequalified Vaccine, and confirm if the licensing process will be completed before shipment.

Country response...

E.1.7 Cold Chain Capacity

Is there sufficient cold chain capacity at all levels to accommodate the vaccine switch?

☐ Yes ☐ No

If **no**, please elaborate on plans to increase capacity/mitigate this need.

Country response...

E.1.8 Procurement & Delivery Mechanism

Does the country procure immunization supplies through UNICEF or the PAHO Revolving Fund? ☐ Yes ☐ No

If **no**, please include a description of the alternative mechanism of supply and delivery of immunization and the vaccines or goods that the country intends to procure through this mechanism.

Country response...

E.2 Switch impact assessment summary

A switch will impact one or more of the six dimensions listed below. Gavi will request each application to have assessed each dimension to surface potential trade-offs between the benefits and downsides of the switch. Please fill in the table based on EPI and or NITAG assessment.

Key Areas for Consideration	Potential switch impact for country	
Ease of use (e.g. single dose, liquid form, oral, dose schedule)	☐ No change ☐ Impacted	<i>Describe the anticipated impact here...</i>
Cold chain, transport, storage requirements	☐ No change ☐ Impacted	<i>Describe the anticipated impact here...</i>

Efficacy, effectiveness or safety	☐ No change ☐ Impacted	<i>Describe the anticipated impact here...</i>
Coverage (acceptability, missed opportunities)	☐ No change ☐ Impacted	<i>Describe the anticipated impact here...</i>
Financial Sustainability (cost, price, wastage)	☐ No change ☐ Impacted	<i>Describe the anticipated impact here...</i>
Supply (availability, security, locally made)	☐ No change ☐ Impacted	<i>Describe the anticipated impact here...</i>

E.3 Operational costs to support the switch

There might be one-time investments associated with the product, presentation, or use switch such as planning, training, supervision, document production and printing, and social mobilisation. These costs need to be considered within the allocated Cash budget.

Are operational costs are included in the overall cash budget? ☐ **Yes** ☐ **No**

E.4 Implementation plan

What is the switch implementation plan?

Please describe the activities that are required for a successful switch, including a timeline of these activities (e.g. identify training needs, cold chain requirements, timeline of activities).

If applying alongside a routine introduction, this plan can be integrated with the new vaccine support request articulated in Annex A.

Country response...